Latest Lapatinib Stories
LONDON, March 17, 2015 /PRNewswire/ -- Executive Summary--The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy,
The Oncology Institute of Hope and Innovation is pleased to announce the recent openings of clinical trials this holiday season. Downey, CA (PRWEB) November
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
NORWALK, Conn., Oct.
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014
The Majority of Surveyed Oncologists Have Already Prescribed Kadcyla, Just Nine Months Post-Launch, According to Findings from Decision Resources Group BURLINGTON, Mass., March 18, 2014 /PRNewswire/
SEATTLE, WA and BOULDER, CO, Feb. 20, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc.
SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc.
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14.
- a slit in a tire to drain away surface water and improve traction.